Myriad Genetics (NASDAQ:MYGN – Get Rating) was downgraded by investment analysts at TheStreet from a “c-” rating to a “d+” rating in a research note issued on Friday, TheStreetRatingsTable reports. Several other equities research analysts have also recently issued reports on MYGN. The Goldman Sachs Group lowered their price objective on shares of Myriad Genetics […]
Brokerages forecast that Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating) will post sales of $170.31 million for the current quarter, Zacks reports. Four analysts have provided estimates for Myriad Genetics’ earnings. The highest sales estimate is $176.10 million and the lowest is $164.60 million. Myriad Genetics posted sales of $189.40 million in the same quarter […]
Wall Street brokerages predict that Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating) will announce sales of $170.31 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Myriad Genetics’ earnings. The lowest sales estimate is $164.60 million and the highest is $176.10 million. Myriad Genetics reported sales of $189.40 million […]
Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Myriad Genetics (NASDAQ:MYGN – Get Rating) issued an update on its FY 2022 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0-$0.20 for the period, compared to the consensus estimate of $0.08. The company issued revenue guidance of $670.00 million-$700.00 million, compared to the consensus revenue estimate of $684.40 […]